Colorectal Cancer

Colorectal Cancer is cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine before the anus). In the United States, it is the fourth most common cancer in men and women. Caught early, it is often curable.

What Causes Colorectal Cancer?

Cancer occurs when a normal cell divides and multiples uncontrollably. Normally cells are regulated in their growth, maturity, division and death by the DNA present in their nucleus. With damage to the DNA the cells may become rogue and multiply uncontrollably to give rise to tumors.

What is Colorectal Cancer?

Colorectal Cancer Diagnosis

Colorectal Cancer Prevention

Colorectal Cancer Management

Colorectal Cancer Prognosis

Colorectal Cancer Symptoms

Colorectal Cancer Pathogenesis

Microbial Dysbiosis and Colorectal Cancer

Colorectal Cancer and Organ Preservation

Latest Colorectal Cancer News and Research

Genes may determine how early life exposures shape the gut microbiome

Early nutritional and antibiotic exposures affect adult gut microbiota, with genetic background and parent-of-origin significantly influencing outcomes.

19 Jun 2025

Heart disease markers may predict future cancer risk

Cancer and heart disease, two leading causes of death worldwide, may be more connected than we previously thought, according to a new UCLA Health study revealing that certain cardiac blood markers can strongly predict future cancer risk-even in people with no history or symptoms of heart disease.

18 Jun 2025

Colorectal cancer patients fare better when diagnosed before other cancers

A new study using one of the world's largest cancer registries shows that patient outcomes can be significantly impacted depending on when colorectal cancer (CRC) is diagnosed related to other cancers.

17 Jun 2025

Paper-based devices show high accuracy in detecting asymptomatic malaria

Devices made with cheap strips of paper have outperformed two other testing methods in detecting malaria infection in asymptomatic people in Ghana – a diagnostic advance that could accelerate efforts to eliminate the disease, researchers say.

16 Jun 2025

Global cancer experts gather in Kenya to improve care across Sub-Saharan Africa

The National Comprehensive Cancer Network (NCCN)-an alliance of leading cancer centers in the United States-is joining the African Cancer Coalition (ACC) to update cancer treatment recommendations during the American Cancer Society (ACS) 2025 Global Academy Regional Workshop: Sub-Saharan Africa, in Nairobi, Kenya, June 9-11.

10 Jun 2025

CT colonography outperforms stool DNA testing in cost and effectiveness

Compared to stool DNA testing, researchers found that CT colonography is a cost-saving and clinically effective method for colorectal cancer screening, according to a study was published today in Radiology, a journal of the Radiological Society of North America.

10 Jun 2025

Tagomics awarded £860 k Innovate UK Biomedical Catalyst grant for detection of colorectal cancer

Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has been awarded £860 k Innovate UK funding as part of the Biomedical Catalyst program for the testing and development of innovative healthcare solutions from Innovate UK, the UK's innovation agency, with the remaining funding contributed by Tagomics.

10 Jun 2025

Structured exercise strengthens immune response in cancer treatment

Exercising during chemotherapy and before surgery may help the body send more immune cells into cancerous tumors, according to a first-of-its-kind pilot study from the University of Surrey and Royal Surrey NHS Foundation Trust.

9 Jun 2025

Biweekly chemotherapy dosing reduces toxicity in colorectal cancer patients

Patients with metastatic colorectal cancer who were treated with a biweekly dose of trifluridine-tipiracil (TAS-102) saw similar treatment effectiveness and reduced toxicity compared with treatment using standard dosing schedules, according to a recent study in The Oncologist that was co-authored by a Fox Chase Cancer Center physician.

6 Jun 2025

Study highlights the lasting toll of colorectal cancer on women's sexual health

A new University of British Columbia-led study is shedding light on a long-overlooked consequence of colorectal cancer: the lasting toll it can take on women's sexual health, even years after treatment ends.

4 Jun 2025

Navigating the dual role of B cells in tumor immunity

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

3 Jun 2025

Exercise after chemo key for colon cancer survival, study finds

Post-chemotherapy exercise significantly boosts disease-free survival in colon cancer patients, underscoring the importance of structured physical activity.

3 Jun 2025

Experts chart path to bring microbiome science into routine clinical care

Despite rapid advances in sequencing and bioinformatics, translating microbiome science into clinical practice presents significant challenges, including the lack of standardized protocols, limited clinical evidence, and logistical barriers. This Cell perspective outlines key actions, standardization, robust trial design, and clinician education to move microbiome diagnostics and therapeutics from bench to bedside.

2 Jun 2025

Anti-inflammatory diet linked to longer survival in colon cancer patients

Patients with colon cancer who consumed an anti-inflammatory diet during a phase 3 clinical trial showed longer overall survival post-treatment compared to those on a proinflammatory diet, according to a Dana-Farber Cancer Institute analysis.

1 Jun 2025

Cancer survivor population in the US expected to surpass 22 million by 2035

The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025 and projected to exceed 22 million by 2035, according to a new report, Cancer Treatment and Survivorship Statistics, 2025, led by the American Cancer Society (ACS).

31 May 2025

Triplet therapy significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the Phase III BREAKWATER trial led by researchers from The University of Texas MD Anderson Cancer Center.

30 May 2025

TRR 417 initiative aims to unlock new treatments for colorectal cancer

In the realm of colorectal cancer treatments beyond surgery and radiation, one key question gained prominence in recent years: Is the tumor's DNA repair system defective, making it "microsatellite unstable"? Around 15 to 20 percent of all tumors have this trait, making them likely candidates for successful immunotherapy.

30 May 2025